AstraZeneca has partnered with Circassia Pharmaceuticals, a respiratory biopharmaceutical company, to develop and market two drugs that treat chronic obstructive pulmonary disease.
Tudorza was approved and launched in the United States in 2012, and Duaklir is expected to be submitted for U.S. regulatory review in 2018, according to an AstraZeneca press release.
"As part of the long-term strategic collaboration with AstraZeneca, we will immediately double our U.S. sales force to promote Tudorza as our priority," Steve Harris, CEO of Circassia Pharmaceuticals, said in the release.
Under the terms of the agreement, the two companies will share U.S. profits from Tudorza equally.
“Tudorza and Duaklir are important components of AstraZeneca’s respiratory franchise globally, and this collaboration will support their commercialization in the U.S. for the benefit of the millions of COPD patients," Mark Mallon, executive vice president of global product and portfolio strategy at AstraZeneca, said in the release.
AstraZeneca, Circassia Pharmaceuticals partner to develop respiratory drugs
Organizations in this Story
Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts